Interim results demonstrate treatment with HMB-001 resulted in >50% reduction in treated bleeds at all tested dose levels
In second oral presentation, Hemab presented first preclinical data for HMB-002, a potential novel treatment for Von Willebrand Disease
Results from lived experience of Glanzmann thrombasthenia (GT360) and Von Willebrand Disease (VWD 360) natural history studies were included in two additional oral presentations
Early results from the study show promise in significantly reducing bleeding, potentially improving the lives of those affected by GT
Another drug, HMB-002, is being explored for Von Willebrand Disease, another bleeding disorder. This drug could help prevent dangerous complications and provide patients with a much-needed new treatment option.
For HMB-001, the study tested different doses to find the safest and most effective amount. Results show that a weekly or biweekly dose can cut bleeding episodes by more than half. However, very high doses may increase the risk of blood clots. The findings help researchers determine the best dosage to improve patient outcomes safely.